Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Molina sold 2,718 shares of the business's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $124.65, for a total value of $338,798.70. Following the sale, the insider directly owned 81,397 shares of the company's stock, valued at approximately $10,146,136.05. This trade represents a 3.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Protagonist Therapeutics Trading Down 0.1%
Shares of Protagonist Therapeutics stock traded down $0.16 during trading hours on Tuesday, reaching $124.67. The stock had a trading volume of 583,063 shares, compared to its average volume of 603,332. The firm has a 50 day simple moving average of $139.45 and a two-hundred day simple moving average of $119.55. The firm has a market capitalization of $8.14 billion, a price-to-earnings ratio of 26.45 and a beta of 1.21. Protagonist Therapeutics, Inc. has a 1 year low of $77.00 and a 1 year high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.57. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%. The business had revenue of $274.41 million for the quarter, compared to analyst estimates of $238.49 million. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.
Hedge Funds Weigh In On Protagonist Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Keating Financial Advisory Services Inc. acquired a new stake in Protagonist Therapeutics in the second quarter valued at approximately $30,000. Allworth Financial LP purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at approximately $31,000. Quantbot Technologies LP purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at approximately $42,000. Parallel Advisors LLC raised its stake in shares of Protagonist Therapeutics by 205.9% during the third quarter. Parallel Advisors LLC now owns 361 shares of the company's stock valued at $51,000 after purchasing an additional 243 shares during the period. Finally, Harbor Investment Advisory LLC acquired a new position in shares of Protagonist Therapeutics during the second quarter worth $89,000. 98.63% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have recently commented on PTGX. Wall Street Zen downgraded shares of Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Citigroup lifted their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a "buy" rating in a report on Monday, August 31st. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the stock from $110.00 to $186.00 in a research report on Monday, August 10th. HC Wainwright increased their price target on Protagonist Therapeutics from $170.00 to $221.00 and gave the company a "buy" rating in a report on Friday, November 6th. Finally, Wedbush reiterated an "outperform" rating on shares of Protagonist Therapeutics in a report on Monday, November 9th. One investment analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of "Buy" and an average target price of $166.67.
Check Out Our Latest Research Report on Protagonist Therapeutics
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.